<?xml version="1.0" encoding="UTF-8"?>
<akn:akomaNtoso xmlns:akn="http://docs.oasis-open.org/legaldocml/ns/akn/3.0"><akn:act><akn:meta><akn:identification source="#cosilico"><akn:FRBRWork prescriptive="true" authoritative="true"><akn:FRBRuri value="/akn/us/usc/42/284i" /><akn:FRBRdate date="2025-12-31" name="retrieval" /><akn:FRBRauthor href="#us-congress" /><akn:FRBRcountry value="us" /></akn:FRBRWork><akn:FRBRExpression><akn:FRBRuri value="/akn/us/usc/42/284i/eng@2025" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /><akn:FRBRlanguage language="en" /></akn:FRBRExpression><akn:FRBRManifestation><akn:FRBRuri value="/akn/us/usc/42/284i/eng@2025/main.xml" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /></akn:FRBRManifestation></akn:identification></akn:meta><akn:body><akn:section eId="sec_284i"><akn:num>284i</akn:num><akn:heading>Autoimmune diseases</akn:heading><akn:content><akn:p>§ 284i. Autoimmune diseases(a) Expansion, intensification, and coordination of activities(1) In generalThe Director of NIH shall expand, intensify, and coordinate research and other activities of the National Institutes of Health with respect to autoimmune diseases.


(2) Allocations by Director of NIHWith respect to amounts appropriated to carry out this section for a fiscal year, the Director of NIH shall allocate the amounts among the national research institutes that are carrying out paragraph (1).


(3) DefinitionThe term “autoimmune disease” includes, for purposes of this section such diseases or disorders with evidence of autoimmune pathogensis 11 So in original. Probably should be “pathogenesis”. as the Secretary determines to be appropriate.



(b) Coordinating Committee(1) In generalThe Secretary shall ensure that the Autoimmune Diseases Coordinating Committee (referred to in this section as the “Coordinating Committee”) coordinates activities across the National Institutes and with other Federal health programs and activities relating to such diseases.


(2) CompositionThe Coordinating Committee shall be composed of the directors or their designees of each of the national research institutes involved in research with respect to autoimmune diseases and representatives of all other Federal departments and agencies whose programs involve health functions or responsibilities relevant to such diseases, including the Centers for Disease Control and Prevention and the Food and Drug Administration.


(3) Chair(A) In generalWith respect to autoimmune diseases, the Chair of the Committee shall serve as the principal advisor to the Secretary, the Assistant Secretary for Health, and the Director of NIH, and shall provide advice to the Director of the Centers for Disease Control and Prevention, the Commissioner of Food and Drugs, and other relevant agencies.


(B) Director of NIHThe Chair of the Committee shall be directly responsible to the Director of NIH.




(c) P</akn:p></akn:content><akn:subsection eId="subsec_284i_a"><akn:num>(a)</akn:num><akn:heading>Expansion, intensification, and coordination of activities</akn:heading><akn:content><akn:p>(a) Expansion, intensification, and coordination of activities</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_284i_b"><akn:num>(b)</akn:num><akn:heading>Coordinating Committee</akn:heading><akn:content><akn:p>(b) Coordinating Committee</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_284i_c"><akn:num>(c)</akn:num><akn:heading>Plan for NIH activities</akn:heading><akn:content><akn:p>(c) Plan for NIH activities</akn:p></akn:content></akn:subsection></akn:section></akn:body></akn:act></akn:akomaNtoso>